Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04194944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04194944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 17, 2020
Completion date
June 30, 2030
Enrollment
261 (actual)
Sites
196

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer